Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mipasetamab, an antibody targeting AXL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Idactamab, an antibody targeting SLC1A5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etevritamab, an antibody targeting EGFR × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emerfetamab, an antibody targeting SIGLEC3 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eluvixtamab, an antibody targeting SIGLEC3 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bavunalimab, an antibody targeting LAG-3 × CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Barecetamab, an antibody targeting HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Voxalatamab, an antibody targeting PSMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vepsitamab, an antibody targeting MUC17 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Latikafusp, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gresonitamab, an antibody targeting Claudin 18.2 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fidasimtamab, an antibody targeting PD-1 × HER2.